Hypertrophic Cardiomyopathy (hcm) Clinical Trials
6 recruiting trials for Hypertrophic Cardiomyopathy (hcm). Eligibility criteria explained in plain English.
TrialFinderData lists 6 Hypertrophic Cardiomyopathy (hcm) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Chinese Academy of Medical Sciences, Fuwai Hospital (1), University of Manchester (1), Peking Union Medical College Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Magnetic Resonance Imaging with Contrast (diagnostic_test, 1 trial), followed by Injection of 68Ga-NI-FAPI, Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation.
Track Hypertrophic Cardiomyopathy (hcm) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
The Application of T1 Mapping in Real-World
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference...
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to...
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related...
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and...
Multimodal Analysis of Endomyocardial Biopsies
The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and...
Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients...
Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Hypertrophic Cardiomyopathy (hcm), with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Hypertrophic Cardiomyopathy (hcm), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Hypertrophic Cardiomyopathy (hcm), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.